FormWeb • raNITIdine

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Add Formweb to your mobile device

Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search results for:

raNITIdine

raNITIdine

Non-formulary H2 - Receptor Blocker Formulary
Therapeutic Interchange

Drug Name	Form	Strength
Zantac	SOLUTION, INJECTABLE	25 mg/mL
Zantac	SYRUP, ORAL	15 mg/mL
Zantac	TABLET, ORAL	75 mg, 150 mg, 300 mg

VIEW MORE Histamine H2-Antagonists
CLASS

Comments:

FDA Recall (April 2020): All ranitidine (IV and Oral) products removed from the market. Recommend and convert to famotdine as needed.

ORDERED FORMULATION

FORMULARY INTERCHANGE

raNITIdine (Zantac)

150 mg PO daily
150 mg PO BID
300 mg PO qhs
raNITIdine oral liquid (PEDS)
50 mg IV q12h
50 mg IV q8h
50 mg IV q6h
100 mg/day continuous infusion
150 mg/day continuous infusion
200 mg/day continuous infusion

famotidine (Pepcid)

20 mg PO qhs
20 mg PO BID
40 mg PO qhs
See Peds famotidine dosing below
20 mg IV daily
20 mg IV q12h
20 mg IV q12h
20 mg/day continuous infusion
40 mg/day continuous infusion
40 mg/day continuous infusion

raNITIdine (Zantac)

75 mg tablet BID

cimetidine (Tagamet)

200 mg tablet BID

Pediatric dosing of famotidine:

< 3 months = 0.5 mg/kg Daily
≥ 3 months = 0.5 mg/kg BID
Maximum pediatric general dose = 40 mg/day
If patient able to take adult tablets with tolerance and dosage, tablets will be used.

If H2 blocker prescribed with PPO, discontinue H2 blocker after 48 hours. Exception if GI physician -- check with physician that H2 blocker is not being used for a non-GI use prior to discontinuing.

Automatic IV to PO conversion per IV to oral conversion guidelines. IV to PO Conversion Guidelines

Updated: 3 April 2020 (FDA Removed from Market), 28 April 2020

Last updated: Apr. 29, 2020

This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.